Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study.
Ryerson CJ, Camp PG, Eves ND, Schaeffer M, Syed N, Dhillon S, Jensen D, Maltais F, O'Donnell DE, Raghavan N, Roman M, Stickland MK, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, Johannson KA, Kalluri M, Khalil N, Kolb M, Manganas H, Morán-Mendoza O, Provencher S, Ramesh W, Rolf JD, Wilcox PG, Guenette JA. Ryerson CJ, et al. Among authors: assayag d. Ann Am Thorac Soc. 2016 Sep;13(9):1640-7. doi: 10.1513/AnnalsATS.201604-267OC. Ann Am Thorac Soc. 2016. PMID: 27348402 Clinical Trial.
Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.
Adams CJ, Shapera S, Ryerson CJ, Assayag D, Johannson KA, Fell CD, Morisset J, Manganas H, Kolb M, Hambly N, Cox G, Khalil N, Marcoux V, Wilcox PG, To T, Sadatsafavi M, Halayko AJ, Gershon A, Garlick K, Fisher JH. Adams CJ, et al. Among authors: assayag d. Respir Med. 2022 Jan;191:106722. doi: 10.1016/j.rmed.2021.106722. Epub 2021 Dec 23. Respir Med. 2022. PMID: 34959146 Free article.
A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Wong AW, Lee TY, Johannson KA, Assayag D, Morisset J, Fell CD, Fisher JH, Shapera S, Gershon AS, Cox G, Halayko AJ, Hambly N, Manganas H, Sadatsafavi M, Wilcox PG, To T, Marcoux V, Khalil N, Kolb M, Ryerson CJ. Wong AW, et al. Among authors: assayag d. Respir Res. 2020 Dec 7;21(1):322. doi: 10.1186/s12931-020-01579-7. Respir Res. 2020. PMID: 33287805 Free PMC article.
Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.
Chen T, Tsai APY, Hur SA, Wong AW, Sadatsafavi M, Fisher JH, Johannson KA, Assayag D, Morisset J, Shapera S, Khalil N, Fell CD, Manganas H, Cox G, To T, Gershon AS, Hambly N, Halayko AJ, Wilcox PG, Kolb M, Ryerson CJ. Chen T, et al. Among authors: assayag d. Respir Res. 2021 Jul 8;22(1):202. doi: 10.1186/s12931-021-01790-0. Respir Res. 2021. PMID: 34238283 Free PMC article.
Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease.
Goobie GC, Ryerson CJ, Johannson KA, Schikowski E, Zou RH, Khalil N, Marcoux V, Assayag D, Manganas H, Fisher JH, Kolb MRJ, Gibson KF, Kass DJ, Zhang Y, Lindell KO, Nouraie SM. Goobie GC, et al. Among authors: assayag d. Am J Respir Crit Care Med. 2022 Feb 15;205(4):459-467. doi: 10.1164/rccm.202109-2065OC. Am J Respir Crit Care Med. 2022. PMID: 34818133
63 results